There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Coherus Biosciences (CHRS), Ovid Therapeutics Inc (OVID) and Stemline Therapeutics Inc (STML) with bullish sentiments.
Coherus Biosciences (CHRS)
In a report released yesterday, Ken Cacciatore from Cowen & Co. maintained a Buy rating on Coherus Biosciences, with a price target of $35. The company’s shares closed yesterday at $11.93.
According to TipRanks.com, Cacciatore is a 3-star analyst with an average return of 2.3% and a 45.8% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Liquidia Technologies Inc, Alder Biopharmaceuticals, and Adamas Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $32.67 average price target, implying a 173.8% upside from current levels. In a report issued on November 2, Maxim Group also maintained a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
Ovid Therapeutics Inc (OVID)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Ovid Therapeutics Inc yesterday. The company’s shares closed yesterday at $5.56, close to its 52-week low of $4.74.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.2% and a 50.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Global Blood Therapeutics.
Ovid Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $20.
Stemline Therapeutics Inc (STML)
Cowen & Co. analyst Boris Peaker reiterated a Buy rating on Stemline Therapeutics Inc yesterday. The company’s shares closed yesterday at $14.58.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.9% and a 43.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Mersana Therapeutics Inc, and Y-Mabs Therapeutics Inc.
Stemline Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $35.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
